Quick Answer
PLIANT THERAPEUTICS, INC. reported Cash and Equivalents of $45.45 million for fiscal year 2025.
PLIANT THERAPEUTICS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $45.45M | -36.2% |
| 2024 | $71.19M | +12.6% |
| 2023 | $63.23M | +87.7% |
| 2022 | $33.69M | -34.8% |
| 2021 | $51.66M | +1.5% |
| 2020 | $50.88M | -40.7% |
| 2019 | $85.81M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $93.73M | +17.7% | +8.0% |
| June 30, 2025 | $86.82M | +8.0% | -5.6% |
| March 31, 2025 | $91.94M | -19.6% | +29.1% |
| December 31, 2024 | $71.19M | +12.6% | -10.6% |
| September 30, 2024 | $79.62M | +38.0% | -1.0% |
| June 30, 2024 | $80.39M | +46.3% | -29.7% |
| March 31, 2024 | $114.30M | +11.5% | +80.8% |
| December 31, 2023 | $63.23M | +87.7% | +9.6% |
- PLIANT THERAPEUTICS, INC. showed a decrease of -36.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, PLIANT THERAPEUTICS, INC.’s cash and equivalents has declined by 47.0% (from $85.81 million to $45.45 million).
- The most recent figure is from PLIANT THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: